2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.
Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.
In the uterine cancer field, there have been changes coming over the last few years as researchers are learning more about microsatellite instability (MSI), which is present in select patients with uterine cancers. Additionally, this MSI may be targeted with the use of PD-1 inhibitors, Dalton adds.
Another tumor that is known to be MSI-high includes colorectal cancer, she explains. In the gynecologic field, uterine cancers seem to be the tumor type that have MSI-high characteristics. However, early research suggest that some ovarian cancers may have this, as well.
Related Content: